InsidersTradesSigma
Track the Damora Therapeutics, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was filed on 7 July 2026 (Levée d'options). Among the most active insiders: Winslow Garrett. All data is accessible without an account.
Analysts rate Damora Therapeutics, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$43.38.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
4 of 4 declarations
Damora Therapeutics, Inc. is a company focused on developing innovative therapies for disease treatment. It is listed on the XNAS market.